EUVIMEDEUVIMED entdecken
Open Access

Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma

Liang Zhao, Yizhen Pang, Jianyang Fang, Jianhao Chen, Yangfan Zhou, Long Sun, Hua Wu, Zhide Guo, Qin Lin, Haojun Chen

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.266183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Liang Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, …. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensive research has been conducted on radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2 (LM3) peptides for imaging of FAP and somatostatin receptor 2 (SSTR2)-positive tumors. In this study, we designed and synthesized a FAPI-LM3 heterobivalent molecule radiolabeled with 68Ga and evaluated its effectiveness in both tumor xenografts and patients with nasopharyngeal carcinoma (NPC).

Methods

The synthesis of FAPI-LM3 was based on the structures of FAPI-46 and LM3. After radiolabeling with 68Ga, its dual-receptor-binding affinity was evaluated in vitro and in vivo. Preclinical studies, including small-animal PET and biodistribution evaluation, were conducted on HT-1080-FAP and HT-1080-SSTR2 tumor xenografts. The feasibility of 68Ga-FAPI-LM3 PET/CT in a clinical setting was evaluated in patients with NPC, and the results were compared with those of 18F-FDG.

Results

68Ga-FAPI-LM3 showed high affinity for both FAP and SSTR2. The tumor uptake of 68Ga-FAPI-LM3 was significantly higher than that of 68Ga-FAPI-46 and 68Ga-DOTA-LM3 in HT-1080-FAP-plus-HT-1080-SSTR2 tumor xenografts. In a clinical study involving 6 NPC patients, 68Ga-FAPI-LM3 PET/CT showed significantly higher uptake than did 18F-FDG in primary and metastatic lesions, leading to enhanced lesion detectability and tumor delineation.

Conclusion

68Ga-FAPI-LM3 exhibited FAPI and SSTR2 dual-receptor-targeting properties both in vitro and in vivo, resulting in improved tumor uptake and retention compared with that observed with monomeric 68Ga-FAPI and 68Ga-DOTA-LM3. This study highlights the clinical feasibility of 68Ga-FAPI-LM3 PET/CT for NPC imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyNasopharyngeal NeoplasmsAnimalsHumansGallium RadioisotopesFluorodeoxyglucose F18Nasopharyngeal CarcinomaTissue DistributionPositron-Emission Tomography

Stichwörter der Autor:innen

PETfibroblast activation proteinheterobivalent moleculenasopharyngeal carcinomasomatostatin receptor 2

Substanzen

Gallium RadioisotopesFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
  • Xiamen Key Laboratory of Radiation Oncology, Department of Radiation Oncology, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China; and.
  • School of Clinical Medicine, Fujian Medical University, Fuzhou, China; leochen0821@foxmail.com linqin05@163.com.
  • Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; leochen0821@foxm…

Zitieren

APA

Zhao, L., Pang, Y., Fang, J., Chen, J., Zhou, Y., Sun, L., Wu, H., Guo, Z., Lin, Q., & Chen, H. (2024). Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266183

Vancouver

Zhao L, Pang Y, Fang J, Chen J, Zhou Y, Sun L, et al. Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266183

BibTeX
@article{Zhao2024,
  author = {Zhao, Liang and Pang, Yizhen and Fang, Jianyang and Chen, Jianhao and Zhou, Yangfan and Sun, Long and Wu, Hua and Guo, Zhide and Lin, Qin and Chen, Haojun},
  title = {Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.266183}
}
Kostenlos starten →